Therapeutics News and Research

RSS

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

University of British Columbia researchers - using an innovative, atom-by-atom substitution method - have uncovered the mechanism by which a particular class of drugs controls irregular heartbeats.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

Cell Therapeutics, Inc. today announced that it met with the U.S. Food and Drug Administration's Division of Oncology Drug Products.

14 Jun 2011

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Fox Chase Cancer Center, one of the nation's leading cancer research and treatment institutions, today announced it has entered into an agreement with Life Technologies Corporation that will underpin a new program to provide next-generation sequencing analysis of solid tumors.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kareus Therapeutics SA, the company focused on the development of novel therapeutics to address high unmet medical need, today announced a broad strategic alliance with Quintiles to progress the development of two of Kareus' pre-clinical programs through clinical trials.

13 Jun 2011

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Cancer Research Technology, the commercial arm of Cancer Research UK, and Paris-based venture capital firm, Kurma Life Sciences Partners (Kurma), have launched a spin-out company, BliNK Therapeutics Ltd, to generate monoclonal antibodies using a novel platform.

13 Jun 2011

Hyperthermia prevents repair of tumor cells

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that a study published in the Proceedings of the National Academy of Sciences demonstrated that hyperthermia can be a powerful tool to inhibit the ability of cancer cells to repair the DNA damage caused by radiation or chemotherapy.

10 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Revance closes $45 million financing

Revance Therapeutics, Inc. today announced the closing of a $45 million financing led by Essex Woodlands Health Ventures and new investor, NovaQuest Capital.

10 Jun 2011

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company's investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.

10 Jun 2011

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

The Scripps Research Institute has been awarded a $2.2 million grant from the National Institutes of Health (NIH) to develop novel therapeutics for the treatment of addiction to multiple substances in a national effort with the University of Kansas.

10 Jun 2011

Respira introduces breakthrough Dry Powder Inhaler

Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, introduces the company's Dry Powder Inhaler (DPI) as a breakthrough solution for the pharmaceutical industry. Based on proprietary drug engine technology (DET), Respira Therapeutics' DPI significantly improves therapeutic performance and enables addressing the unmet medical needs of patients with severe respiratory diseases.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

9 Jun 2011

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

TGen Drug Development (TD2) and Imaging Endpoints have teamed up to enable the rapid development of anti-cancer drugs and deliver them faster to patients in need, the companies announced today.

9 Jun 2011

Therapeutics News and Research

Galectin strengthens cancer drug patent portfolio in Europe

Researchers reveal how anti-arrhythmic drugs control irregular heartbeats

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

CTI completes pixantrone NDA resubmission meeting with FDA's Division of Oncology Drug Products

Life Technologies, Fox Chase partner to provide next-generation sequencing analysis of solid tumors

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Trimeris, Synageva enter definitive merger agreement

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Quintiles, Kareus partner to advance KU-046 diabetes drug candidate into clinical trials

Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

Hyperthermia prevents repair of tumor cells

Larger trial study needed to decide fate of niacin

Revance closes $45 million financing

FDA accepts ZIOPHARM's IND for ZIN ATI-001 to treat melanoma

Scripps Research receives $2.2M NIH grant to develop novel therapeutics for substance abuse

Respira introduces breakthrough Dry Powder Inhaler

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

JDRF, Selecta Biosciences partner to develop type 1 diabetes vaccine

TD2, Imaging Endpoints team up to enable rapid development of anti-cancer drugs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News